Literature DB >> 27467764

Differential body weight, blood pressure and placental inflammatory responses to normal versus high-fat diet in melanocortin-4 receptor-deficient pregnant rats.

Frank T Spradley1, Ana C Palei, Joey P Granger.   

Abstract

OBJECTIVES: Although obesity increases the risk for hypertensive disorders of pregnancy, the mechanisms remain unclear. Neural melanocortin-4 receptor (MC4R) deficiency causes hyperphagia and obesity. Effects of MC4R deficiency on body weight, blood pressure (BP) and placental inflammatory responses to high-fat diet (HFD) are unknown. We tested two hypotheses: MC4R deficiency results in higher body weight, BP and placental inflammation under normal-fat diet (NFD) conditions and HFD exaggerates these responses in MC4R-deficient pregnant rats.
METHODS: MC4R and MC4R rats were maintained on NFD (13% kcal fat) or HFD (40% kcal fat) for ∼15 weeks, then measurements made on gestational day 19.
RESULTS: MC4R pregnant rats had greater body mass and total body fat and visceral adipose tissue weights along with greater circulating total cholesterol (TC) and leptin levels than MC4R rats regardless of diet. On NFD, circulating adiponectin levels were lower and placental TNFα levels and BP (conscious with carotid catheter) were higher in these heavier rats. Circulating adiponectin levels were lower and placental TNFα levels and BP were higher in MC4R rats compared with NFD controls. These parameters were not affected by HFD in the already heavier and hypertensive MC4R pregnant rats.
CONCLUSION: Obesity in MC4R deficiency and HFD in MC4R rats result in higher BP and placental inflammation during pregnancy. However, HFD did not exaggerate these responses in already obese MC4R pregnant rats. These data suggest that obesity and HFD are independently related to hypertension and placental inflammation in pregnancy.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27467764      PMCID: PMC5310251          DOI: 10.1097/HJH.0000000000001059

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  47 in total

Review 1.  Epidemiology of preeclampsia: impact of obesity.

Authors:  Arun Jeyabalan
Journal:  Nutr Rev       Date:  2013-10       Impact factor: 7.110

2.  Leptin-responsive GABAergic neurons regulate fertility through pathways that result in reduced kisspeptinergic tone.

Authors:  Cecilia Martin; Víctor M Navarro; Serap Simavli; Linh Vong; Rona S Carroll; Bradford B Lowell; Ursula B Kaiser
Journal:  J Neurosci       Date:  2014-04-23       Impact factor: 6.167

3.  A frameshift mutation in MC4R associated with dominantly inherited human obesity.

Authors:  G S Yeo; I S Farooqi; S Aminian; D J Halsall; R G Stanhope; S O'Rahilly
Journal:  Nat Genet       Date:  1998-10       Impact factor: 38.330

4.  A frameshift mutation in human MC4R is associated with a dominant form of obesity.

Authors:  C Vaisse; K Clement; B Guy-Grand; P Froguel
Journal:  Nat Genet       Date:  1998-10       Impact factor: 38.330

Review 5.  The brain melanocortin system, sympathetic control, and obesity hypertension.

Authors:  Alexandre A da Silva; Jussara M do Carmo; Zhen Wang; John E Hall
Journal:  Physiology (Bethesda)       Date:  2014-05

6.  Associations of maternal obesity with blood pressure and the risks of gestational hypertensive disorders. The Generation R Study.

Authors:  Romy Gaillard; Eric A P Steegers; Albert Hofman; Vincent W V Jaddoe
Journal:  J Hypertens       Date:  2011-05       Impact factor: 4.844

7.  Factors That Predict the Development of Hypertension in Women With Pregnancy-Induced Hypertension.

Authors:  Noa Shopen; Eyal Schiff; Nira Koren-Morag; Ehud Grossman
Journal:  Am J Hypertens       Date:  2015-05-26       Impact factor: 2.689

8.  Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004.

Authors:  Anne B Wallis; Audrey F Saftlas; Jason Hsia; Hani K Atrash
Journal:  Am J Hypertens       Date:  2008-03-13       Impact factor: 2.689

9.  Diet-genotype interactions in the development of the obese, insulin-resistant phenotype of C57BL/6J mice lacking melanocortin-3 or -4 receptors.

Authors:  Gregory M Sutton; James L Trevaskis; Matthew W Hulver; Ryan P McMillan; Nathan J Markward; M Josephine Babin; Emily A Meyer; Andrew A Butler
Journal:  Endocrinology       Date:  2006-02-09       Impact factor: 4.736

10.  Intracellular retention is a common characteristic of childhood obesity-associated MC4R mutations.

Authors:  Cecile Lubrano-Berthelier; Emmanuelle Durand; Beatrice Dubern; Astrid Shapiro; Paul Dazin; Jacques Weill; Camille Ferron; Philippe Froguel; Christian Vaisse
Journal:  Hum Mol Genet       Date:  2003-01-15       Impact factor: 6.150

View more
  5 in total

1.  Melanocortin-4 Receptor Deficiency Attenuates Placental Ischemia-Induced Hypertension in Pregnant Rats.

Authors:  Frank T Spradley; Ana C Palei; Christopher D Anderson; Joey P Granger
Journal:  Hypertension       Date:  2019-01       Impact factor: 10.190

2.  Administration of recombinant human placental growth factor decreases blood pressure in obese hypertensive pregnant rats.

Authors:  Ana C Palei; Adelene Y Tan; Woo S Joo; Paul Kussie; Christopher D Anderson; Barbara A Wilson; Frank T Spradley
Journal:  J Hypertens       Date:  2020-11       Impact factor: 4.776

3.  Cardiac, renal and uterine hemodynamics changes throughout pregnancy in rats with a prolonged high fat diet from an early age.

Authors:  Lidia Oltra; Virginia Reverte; Antonio Tapia; Juan M Moreno; Francisco J Salazar; María T Llinás
Journal:  PLoS One       Date:  2020-06-30       Impact factor: 3.240

4.  Cardiac hypertrophy with obesity is augmented after pregnancy in C57BL/6 mice.

Authors:  Chen Che; Kayla Dudick; Robin Shoemaker
Journal:  Biol Sex Differ       Date:  2019-12-16       Impact factor: 5.027

5.  High-fat diet from parental generation exaggerates body and adipose tissue weights in pregnant offspring.

Authors:  Frank T Spradley
Journal:  PLoS One       Date:  2020-08-20       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.